Cadrenal Therapeutics, Inc. Common Stock
Price Action
Technical Summary
DOWNTRENDCadrenal Therapeutics, Inc. Common Stock is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 10), showing significant lag compared to the market leaders. Earnings growth of 40% provides fundamental context to the price action. Investors should exercise caution due to high volatility (100% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.54 | +11.42% | ABOVE |
| 50 SMA | $6.23 | -1.02% | BELOW |
| 100 SMA | $6.76 | -8.76% | BELOW |
| 150 SMA | $8.57 | -27.97% | BELOW |
| 200 SMA | $9.53 | -35.25% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CVKD in an uptrend right now?
CVKD has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.
Is CVKD overbought or oversold?
CVKD's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is CVKD outperforming the market?
CVKD has a Relative Strength (RS) Rating of 10 out of 99. CVKD is currently lagging the broader market.
Where is CVKD in its 52-week range?
CVKD is trading at $6.17, which is 37% of its 52-week high ($16.50) and 16% above its 52-week low ($4.20).
How volatile is CVKD?
CVKD has a Beta of 2.12 and 52-week volatility of 100%. It's more volatile than the S&P 500 - expect bigger swings.